Tue, November 26, 2019
Mon, November 25, 2019
Fri, November 22, 2019

Joel Beatty Upgraded (ARWR) to Buy and Increased Target to $70 on, Nov 25th, 2019

Joel Beatty of Baird, Upgraded "Arrowhead Pharmaceuticals, Inc." (ARWR) to Buy and Increased Target from $39 to $70 on, Nov 25th, 2019.

Joel has made no other calls on ARWR in the last 4 months.



There are 3 other peers that have a rating on ARWR. Out of the 3 peers that are also analyzing ARWR, 1 agrees with Joel's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Elemer Piros of "Cantor Fitzgerald" Maintained at Hold with Increased Target to $50 on, Tuesday, November 19th, 2019


These are the ratings of the 2 analyists that currently disagree with Joel


  • Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $59 on, Wednesday, November 13th, 2019
  • Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $45 on, Tuesday, October 22nd, 2019